Cargando…

Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study

INTRODUCTION: Few studies have assessed the efficacy and safety of micafungin in patients with proven or probable invasive aspergillosis (IA). This was the aim of the current study, which was conducted in 22 hospitals in China, where micafungin was approved for treatment of IA in 2006. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Yu, Song, Yongping, Zhou, Fang, Liu, Ting, Jiang, Ming, Zhao, Xielan, Huang, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392632/ https://www.ncbi.nlm.nih.gov/pubmed/29384927 http://dx.doi.org/10.1097/MD.0000000000009443

Ejemplares similares

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
por: Wiederhold, Nathan P, et al.
Publicado: (2009)

Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis
por: Grant, Victoria C., et al.
Publicado: (2022)

Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study
por: Viscoli, Claudio, et al.
Publicado: (2014)

Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients
por: Cesaro, Simone, et al.
Publicado: (2007)

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis()
por: Denning, David W., et al.
Publicado: (2006)

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
por: Kohno, S., et al.
Publicado: (2012)

Pooled analysis of safety for micafungin
por: Cornely, OA, et al.
Publicado: (2008)

Cardiac Safety of High-dose Micafungin
por: Stover, Kayla R., et al.
Publicado: (2017)

Effectiveness and safety of morinidazole in the treatment of pelvic inflammatory disease: A multicenter, prospective, open-label phase IV trial
por: Zhou, Ting, et al.
Publicado: (2022)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

Micafungin for the treatment of pediatric invasive fungal infections
por: Arrieta, A, et al.
Publicado: (2009)

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study
por: Zheng, Xiaoyun, et al.
Publicado: (2018)

Proven Fatal Invasive Aspergillosis in a Patient with COVID-19 and Staphylococcus aureus Pneumonia
por: van Someren Gréve, Frank, et al.
Publicado: (2021)

Safety and Effectiveness of Dapoxetine On Demand in Chinese Men With Premature Ejaculation: Results of a Multicenter, Prospective, Open-Label Phase IV Study
por: Peng, Jing, et al.
Publicado: (2021)

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
por: Yan, Min, et al.
Publicado: (2022)

Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidaemia
por: Kuse, ER, et al.
Publicado: (2008)

Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin
por: Shirazi, Fazal, et al.
Publicado: (2015)

Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review
por: Bernardeschi, Céline, et al.
Publicado: (2015)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study
por: Kim, Ryul, et al.
Publicado: (2017)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao, Jingping, et al.
Publicado: (2017)

Diagnostic efficacy of metagenomic next generation sequencing in bronchoalveolar lavage fluid for proven invasive pulmonary aspergillosis
por: Jia, Hongxia, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin – case study and brief literature review
por: Barańska, Marta, et al.
Publicado: (2017)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

SUN-094 Long-Term Safety and Efficacy of Leuprorelin in Treating Central Precocious Puberty: A Large, Open-Label, Multicenter, Phase IV Study in China
por: Luo, Xiaoping, et al.
Publicado: (2020)

Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study
por: Kotsopoulou, Maria, et al.
Publicado: (2019)

In Favor of Controlling Proven, but Not Probable, Causes of Cancer
por: Erren, Thomas C., et al.
Publicado: (2011)

Proven Nasal and Pulmonary Aspergillosis in Patient with Severe Fever with Thrombocytopenia Syndrome
por: Seong, Gil Myeong, et al.
Publicado: (2022)

Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial
por: Lee, Chien-Te, et al.
Publicado: (2022)

A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy
por: Han, Sang Youb, et al.
Publicado: (2022)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

Review of the pharmacology and clinical studies of micafungin
por: Bormann, Alison M, et al.
Publicado: (2009)

Pharmacokinetics of Micafungin in Critically Ill Patients
por: Gastine, Silke, et al.
Publicado: (2019)

Impact of early catheter removal during treatment of invasive candidiasis: analysis from two phase 3 micafungin trials
por: Nucci, M, et al.
Publicado: (2009)

Clinical Characteristics and Prognostic Risk Factors of Patients With Proven Invasive Pulmonary Aspergillosis: A Single-Institution Retrospective Study
por: Tong, Xiang, et al.
Publicado: (2021)

Proven COVID‐19—associated pulmonary aspergillosis in patients with severe respiratory failure
por: Fortarezza, Francesco, et al.
Publicado: (2021)

Proven pulmonary aspergillosis in a COVID-19 patient: A case report
por: Khodavaisy, Sadegh, et al.
Publicado: (2021)

Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Patients Undergoing Procedure-Type Sedation
por: Jooste, Edmund H., et al.
Publicado: (2017)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jtuiafkbc096oejqqdluqacbrk